Mustang Bio Inc (MBIO)

US · Healthcare · Biotechnology

$0.49-2.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.1M

EPS

$-0.16

Market cap

$3.8M

Forward P/E

0.0

P/B

0.51

Book value

$1.00

EPS (TTM)

$-0.42

52-week high

$1.85

52-week low

$0.51

50-day MA

$0.60

200-day MA

$0.81

Beta

2.05

Analysts rate Mustang Bio Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Insiders

8.02%

Institutions

9.93%

Fund	Stake
Kestra Advisory Services, LLC	2.60%
Geode Capital Management, LLC	1.22%
BlackRock Inc	1.12%
Citadel Advisors Llc	0.70%
CFO4Life Group, LLC	0.44%
Vanguard Fiduciary Trust Co	0.42%
Vanguard Capital Management, LLC	0.34%
Two Sigma Investments LLC	0.22%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mustang Bio Inc — free to start.

Data updated 2026-09-18.